Chemistry of tricyclic-based heterocycles as useful scaffolds for phosphodiesterase 10A ligands

Mini-Reviews in Organic Chemistry

Volumn 10, Issue 2, 2013, Pages 123-140

  Asproni, Battistina ^a   Dore, Antonio ^a   Murineddu, Gabriele ^a   Pinna, Gerard Aime ^a  

^a Department of Chemistry and Pharmacy ^*  (Italy)

Author keywords

Linear and angular tricyclic based heterocycles; PDE10A activity; Synthetic procedures

Indexed keywords

ESTERS; NEURODEGENERATIVE DISEASES; SCAFFOLDS;

CENTRAL NERVOUS SYSTEMS; HETEROCYCLES; HUNTINGTON DISEASE; LINEAR AND ANGULAR TRICYCLIC-BASED HETEROCYCLE; MOLECULAR ARCHITECTURE; PHARMACEUTICAL COMPANY; PHOSPHODIESTERASE 10A ACTIVITY; PHOSPHODIESTERASES; SYNTHETIC PROCEDURES; THERAPEUTIC AGENTS;

LIGANDS;

EID: 84893000320     PISSN: 1570193X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570193X11310020003     Document Type: Review

References (66)

1. Conti, M.; Beavo, J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem., 2007, 76, 481-511.
2. Soderling, S. H.; Bayuga, S. J.; Beavo, J. A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc. Natl. Acad. Sci. USA, 1999, 96, 7071-7076.
3. Fujishige, K.; Kotera, J.; Michibata, H.; Yuasa, K.; Takebayashi, S.; Okumura, K.; Omori, K. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J. Biol. Chem., 1999, 274, 18438-18445.
4. Loughney, K.; Snyder, P. B.; Uher, L.; Rosman, G. J.; Ferguson, K.; Florio, V. A. Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase. Gene, 1999, 234, 109-117.
5. Kotera, J.; Fujishige, K.; Yuasa, K.; Omori, K. Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP. Biochem. Biophys. Res. Commun., 1999, 261, 551-577.
6. Seeger, T. F.; Bartlett, B.; Coskran, T. M.; Culp, J. S.; James, L. C.; Krull, D. L.; Lanfear, J.; Ryan, A. M.; Schmidt, C. J.; Strick, C. A.; Varghese, A. H.; Williams, R. D.; Wylie, P. G.; Menniti, F. S. Immunohistochemical localization of PDE10A in the rat brain. Brain Res., 2003, 985, 113-126.
7. Menniti, F. S.; Faraci, W. S.; Schmidt, C. J. Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov., 2006, 5, 660-670.
8. Giampà C.; Patassini, S.; Borreca, A.; Laurenti D.; Marullo, F.; Bernardi, G.; Menniti, F. S.; Fusco, F. R. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease. Neurobiol. Disease, 2009, 34, 450-456.
9. Kehler, J.; Ritzén, A.; Greve, D. R. The potential therapeutic use of phosphodiesterase 10 inhibitors. Expert Opin. Ther. Patents, 2007, 17, 147-158.
10. Menniti, F. S. Chappie, T. A.; Humphrey, J. M.; Schmidt, C. J. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr. Opin. Invest. Drugs, 2007, 8, 54-59.
11. Chappie, T.; Humphrey, J.; Menniti, F.; Schmidt, C. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape. Curr. Opin. Drug Discov. Devel., 2009, 12, 458-467.
12. Kehler, J.; Kilburn, J. P. Patented PDE10A inhibitors: novel compounds since 2007. Expert Opin. Ther. Patents, 2009, 19, 1715-1725.
13. Kehler, J.; Nielsen, J. PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr. Pharm. Design. 2011, 17, 137-150.
14. Chappie, T. A; Helal, C. J.; Hou, X. Current landscape of phosphodiesterase 10A (PDE10A) inhibition. J. Med. Chem., 2012, 55, 7299-7331.
15. Hoefgen, N.; Grunwald, C.; Langen, B. Targeting PDE10A in schizophrenia. Drugs of the Future, 2012, 37, 577-589.
16. Kehler, J. Phosphodiesterase 10A inhibitors: a 2009-2012 patent update. Expert Opin. Ther. Patents, 2013, 23, 31-45.
17. Pfizer Products Inc. Lebel, L. A. Use of selective PDE10 inhibitors for the treatment of central nervous system disorders. EP1250923A2, October 03, 2002.
18. Siuciak, J. A.; Chapin, D. S.; Harms, J. F.; Lebel, L. A.; McCarthy, S. A.; Chambers, L.; Shrikhande, A.; Wong, S.; Menniti, F. S.; Schmidt, C. J. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology, 2006, 51, 386-396.
19. Verhoest, P. R.; Chapin, D. S.; Corman, M.; Fonseca, K.; Harms, J. F.; Hou, X.; Marr, E. S.; Menniti, F. S.; Nelson, F.; O'Connor, R.; Pandit, J.; Proulx-LaFrance, C.; Schmidt, A. W.; Schmidt,. C. J. Suiciak, J. A.; Liras, S. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J. Med. Chem., 2009, 52, 5188-5196.
20. Schmidt, C. J.; Chapin, D. S.; Cianfrogna, J.; Corman, M. L.; Hajos, M.; Harms, J. F.; Hoffman, W. E.; Lebel, L. A.; McCarthy, S. A.; Nelson, F. R.; Proulx-LaFrance, C.; Majchrzak, M. J.; Ramirez, A. D.; Schmidt, K.; Seymour, P. A.; Siuciak, J. A.; Tingley III, F. D.; Williams, R. D.; Verhoest, P. R.; Menniti, F. S. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J. Pharmacol. Exp. Ther., 2008, 325, 681-690.
21. Grauer, S. M.; Pulito, V. L.; Navarra, R. L.; Kelly, M. P.; Kelley, C.; Graf, R.; Langen, B.; Logue, S.; Brennan, J.; Jiang, L.; Charych, E.; Egerland, U.; Liu, F.; Marquis, K. L.; Malamas, M.; Hage, T.; Comery, T. A.; Brandon, N. J. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J. Pharmacol. Exp. Ther., 2009, 331, 574-590.
22. Chappie, T. A.; Humphrey, J. M.; Allen, M. P.; Estep, K. G.; Fox, C. B.; Lebel, L. A.; Liras, S.; Marr, E. S.; Menniti, F. S.; Pandit, J.; Schmidt, C. J.; Tu, M.; Williams, R. D.; Yang, F. V. Discovery of a series of 6, 7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors. J. Med. Chem., 2007, 50, 182-185.
23. Helal, C. J.; Kang, Z.; Hou, X.; Pandit, J.; Chappie, T. A.; Humphrey, J. M.; Marr, E. S.; Fennell, K. F.; Chenard, L. K.; Fox, C.; Schmidt, C. J.; Williams, R. D.; Chapin, D. S.; Siuciak, J.; Lebel, L.; Menniti, F.; Cianfrogna, J.; Fonseca, K. R.; Nelson, F. R.; O'Connor, R.; MacDougall, M.; McDowell, L.; Liras, S. Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia. J. Med. Chem., 2011, 54, 4536-4547.
24. Bayer Corporation. Niewöhner, U.; Bauser, M.; Ergüden, J.-K.; Flubacher, D.; Naab, P.; Repp, T.-O.; Stoltefuss, J.; Burkhardt, N.; Sewing, A.; Schauer, M.; Schlemmer, K.-H.; Weber, O.; Boyer, S. J.; Miglarese, M. Pyrrolo[2, 1-a]dihydroisoquinolines and their use as phosphodiesterase 10A inhibitors. WO2002048144A1, June 20, 2002.
25. Bayer Corporation. Bauser, M.; Ergüden, J.-K.; Flubacher, D.; Naab, P.; Repp, T.-O.; Stoltefuss, J.; Burkhardt, N.; Sewing, A.; Schauer, M.; Schlemmer, K.-H.; Weber, O.; Boyer, S. J.; Miglarese, M.; Ying, S. 3-Substituted pyrrolo[2, 1-a]isoquinoline derivatives. WO2003014117A1, February 20, 2003.
26. Bayer Corporation. Bauser, M.; Ergüden, J.-K.; Flubacher, D.; Naab, P.; Repp, T.-O.; Stoltefuss, J.; Burkhardt, N.; Sewing, A.; Schauer, M.; Schlemmer, K.-H.; Weber, O.; Boyer, S. J.; Miglarese, M.; Fan, J.; Phillips, B.; Raudenbush, B. C.; Wang, Y. Pyrrolo[2, 1-a]isoquinoline derivatives. WO2003014116A1, February 20, 2003.
27. Bayer Corporation. Niewöhner, U.; Bauser, M.; Ergüden, J.-K.; Flubacher, D.; Naab, P.; Repp, T.-O.; Stoltefuss, J.; Burkhardt, N.; Sewing, A.; Schauer, M.; Weber, O.; Schlemmer, K.-H.; Boyer, J. S.; Miglarese, M. 3-Substituted pyrrolo[2, 1-a]isoquinoline derivatives. WO2003014115A1, February 20, 2003.
28. Bayer Corporation. Zhang, C.; Fan, D.; Wang, Y.; Li, T.; Boyer, S. J.; Burke, J.; Raudenbush, B. C.; Wong, W. C.; Ying, S.; Wang, M.; Zhao, Q.; Carter, C. A.; Burkhardt, N.; Pernerstorfer, J.; Niewoehner, M. 2-Substituted pyrrolo[2, 1-a]isoquinoline against cancer. WO2003051877A1, June 26, 2003.
29. Bayer Pharmaceuticals Corporation. Sweet, L. Methods for treating diabetes and related disorders using PDE10A inhibitors. WO2005012485A2, February 10, 2005.
30. Meyer, H. Pyrrole durch cyclisierende Michael-addition von enaminen. Liebigs Ann. Chem., 1981, 9, 1534-1544.
31. Grob, C. A.; Schad, H. P. Eine neue pyrrolring-synthese. II. Teil. Untersuchungen in der pyrrolreihe. Helv. Chim. Acta., 1955, 38, 1121-1127.
32. Korotaev, V. Y.; Sosnovskikh, V. Y.; Barkov, A. Y.; Slepukhin, P. A.; Ezhikova, M. A.; Kodess, M. I.; Shklyaev, Y. V. A simple synthesis of the pentacyclic lamellarin skeleton from 3-nitro-2-(trifluoromethyl)-2H-chromenes and 1-methyl(benzyl)-3, 4-dihydroisoquinolines. Tetrahedron, 2011, 67, 8685-8698.
33. Altana Pharma AG. Baer, T.; Vennemann, M. Pyrrolodihydroisoquinoline derivatives as PDE10 inhibitors. WO2005002579A1, January 13, 2005.
34. Altana Pharma AG. Vennemann, M.; Baer, T.; Braunger, J. Pyrrolo-dihydroisoquinolines as PDE10 inhibitors. WO2005003129A1, January 13, 2005.
35. Altana Pharma AG. Vennemann, M.; Baer, T.; Braunger, J. Gekeler, V. Novel pyrrolodihydroisoquinolines useful in the treatment of cancer. WO2005003130A1, January 13, 2005.
36. Altana Pharma AG. Vennemann, M.; Bär, T.; Braunger, J. Ciapetti, P.; Contreras, J.-M.; Wermuth, C. G. Novel pyrrolodihydroisoquinolines as PDE10 inhibitors. WO2006089815A1, August 31, 2006.
37. Elbion AG. Höfgen, N.; Stange, H.; Langen, B.; Egerland, U.; Schindler, R.; Gasparic, A.; Rundfeldt, C. 4-Amino-pyrido[3, 2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them. WO2007137819A1, December 6, 2007.
38. Elbion AG. Höfgen, N.; Stange, H.; Langen, B.; Egerland, U.; Schindler, R.; Pfeifer, T.; Rundfeldt, C. Pyrido[3, 2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them. WO2007137820A1, December 6, 2007.
39. Elbion GMBH. Höfgen, N.; Stange, H.; Langen, B.; Egerland, U.; Schindler, R.; Gasparic, A.; Rundfeldt, C.; Pfeifer, T. Methods of treating obesity and metabolic disorders. WO2009068246A2, June 4, 2009.
40. Elbion GMBH. Höfgen, N.; Stange, H.; Langen, B.; Egerland, U.; Schindler, R. Aryl and heteroaryl fused imidazo[1, 5-a]pyrazines as inhibitors of phosphodiesterase 10. WO2009068320A1, June 4, 2009.
41. Wyeth, Elbion GMBH. Malamas, M. S.; Ni, Y.; Erdei, J. J.; Stange, H.; Schindler, R.; Höfgen, N.; Egerland, U.; Langen, B. Pyrido[3, 2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10. WO2009070583A1, June 4, 2009.
42. Wyeth, Elbion GMBH. Malamas, M. S.; Ni, Y.; Erdei, J. J.; Stange, H.; Schindler, R.; Höfgen, N.; Egerland, U.; Langen, B. Aryl and heteroaryl fused imidazo[1, 5-a]pyrazines as inhibitors of phosphodiesterase 10. WO2009070584A1, June 4, 2009.
43. Wyeth, Biotie Therapies GMBH. Malamas, M. S.; Ni, Y.; Erdei, J. J.; Egerland, U.; Langen, B. Substituted imidazo[1, 5-a]quinoxalines as inhibitors of phosphodiesterase 10. WO2010138833A1, December 2, 2010.
44. Höfgen, N.; Stange, H.; Schindler, R.; Lankau, H.-J.; Grunwald, C.; Langen, B.; Egerland, U.; Tremmel, P.; Pangalos, M. N.; Marquis, K. L.; Hage, T.; Harrison, B. L.; Malamas, M. S.; Brandon, N. J.; Kronbach, T. Discovery of imidazo[1, 5-a]pyrido[3, 2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors. J. Med. Chem., 2010, 53, 4399-4411.
45. Langen, B.; Dost, R.; Egerland, U.; Stange, H.; Hoefgen, N. Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test. Psychopharmacology, 2012, 221, 249-259.
46. Malamas, M. S.; Ni, Y.; Erdei, J.; Stange, H.; Schindler, R.; Lankau, H.-J.; Grunwald, C.; Fan, K. Y.; Parris, K.; Langen, B.; Egerland, U.; Hage, T.; Marquis, K. L.; Grauer, S.; Brennan, J.; Navarra, R.; Graf, R.; Harrison, B. L.; Robichaud, A.; Kronbach, T.; Pangalos, M. N.; Hoefgen, N; Brandon, N. J. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors. J. Med. Chem., 2011, 54, 7621-7638.
47. Biotie Therapies GMBH, Wyeth. Stange, H.; Langen, B.; Egerland, U.; Hoefgen, N.; Priebs, M.; Malamas, M. S.; Erdei, J. J.; Ni, Y. Triazine derivatives as inhibitors of phosphodiesterases. WO2010054253A1, May 14, 2010.
48. Biotie Therapies GMBH, Wyeth. Stange, H.; Langen, B.; Egerland, U.; Hoefgen, N.; Priebs, M.; Malamas, M. S.; Erdei, J. J.; Ni, Y. Imidazo[5, 1-c][1, 2, 4]benzotriazine derivatives as inhibitors of phosphodiesterases. WO2010054260A1, May 14, 2010.
49. Malamas, M. S.; Stange, H.; Schindler, R.; Lankau, H.-J.; Grunwald, C.; Langen, B.; Egerland, U., Hage, T.; Ni, Y.; Erdei, J.; Fan, K. Y.; Parris, K.; Marquis, K. L.; Grauer, S.; Brennan, J.; Navarra, R.; Graf, R.; Harrison, B. L.; Robichaud, A.; Kronbach, T.; Pangalos, M. N.; Brandon, N. J.; Hoefgen, N. Novel triazines as potent and selective phosphodiesterase 10A inhibitors. Bioorg. Med. Chem. Lett., 2012, 22, 5876-5884.
50. Schering Corporation. Ho, G. D.; Yang, S.-W.; Smith, E. M.; McElroy, W. T.; Basu, K.; Smotryski, J.; Tan, Z.; McKittrick, B. A.; Tulshian, D. B. Substituted pyrazoloquinolines and derivatives thereof. WO2010062559A1, June 3, 2010.
51. Schmidt, R. R.; Huth, H. Ring verengung bei 6H-1, 3, 4-thiadiazinen. Tetrahedron Lett., 1975, 1, 33-36.
52. Pfeiffer, W.-D.; Dilk, E.; Roßberg, H.; Langer, P. Synthesis and reactivity of 3, 4-dimethyl-4H-1, 3, 4-thiadiazines. Synlett, 2003, 15, 2392-2394.
53. Yang, S.-W.; Smotryski, J.; McElroy, W. T.; Tan, Z.; Ho, G.; Tulshian, D., Greenlee, W. J.; Guzzi, M.; Zhang, X.; Mullins, D.; Xiao, L.; Hruza, A.; Chan, T.-M.; Rindgen, D.; Bleickardt, C.; Hodgson, R. Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia. Bioorg. Med. Chem. Lett., 2012, 22, 235-239.
54. Ho, G. D.; Yang, S.-W.; Smotryski, J.; Bercovici, A., Nechuta, T.; Smith, E. M.; McElroy, W.; Tan, Z.; Tulshian, D.; McKittrick, B.; Greenlee, W. J.; Hruza, A.; Xiao, L.; Rindgen, D.; Mullins, D.; Guzzi, M.; Zhang, X.; Bleickardt, C.; Hodgson, R. The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia. Bioorg. Med. Chem. Lett., 2012, 22, 1019-1022.
55. McElroy, W. T; Tan, Z.; Basu, K.; Yang, S.-W.; Smotryski, J.; Ho, G. D.; Tulshian, D.; Greenlee, W. J.; Mullins, D.; Guzzi, M.; Zhang, X.; Bleickardt, C.; Hodgson, R. Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound. Bioorg. Med. Chem. Lett., 2012, 22, 1335-1339.
56. Schering Corporation. Ho, G. D.; Seganish, W. M.; Tulshian, D. B.; Timmers, C. M.; Rijn, R. D. V.; Loozen, H. J. J. Dihydroimidazoisoquinoline derivatives useful as PDE10 inhibitors. WO2011008597A1, January 20, 2011.
57. Seganish, W. M.; Bercovici, A.; Ho, G. D.; Loozen, H. J. J.; Timmers, C. M.; Tulshian, D. A synthesis of dihydroimidazo[5, 1-a]isoquinolines using a sequential Ugi-Bischler-Napieralski reaction sequence. Tetrahedron Lett., 2012, 53, 903-905.
58. Ho, G. D.; Seganish, W. M.; Bercovici, A.; Tulshian, D.; Greenlee, W. J.; Rijn, R. V.; Hruza, A.; Xiao, L.; Rindgen, D.; Mullins, D.; Guzzi, M.; Zhang, X.; Bleickardt, C.; Hodgson, R. The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorg. Med. Chem. Lett., 2012, 22, 2585-2589.
59. Glenmark Pharmaceuticals S. A. Gharat, L. A.; Gajera, J. M.; Khairatkar-Joshi, N.; Bajpai, M. Tricycle compounds as phosphodiesterase-10 inhibitors. WO2011132051A2, October 27, 2011.
60. H. Lundbeck A/S. Kehler, J.; Ritzén, A.; Langgård, M.; Nielsen, J.; Farah, M. Leth-Petersen, S.; Kilburn, J. P. Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitors. WO2012007006A1, January 19, 2012.
61. Kehler, J.; Ritzén, A.; Langgård, M.; Leth-Petersen, S.; Farah, M. M.; Bundgaard, C.; Christoffersen, C. T.; Nielsen, J.; Kilburn, J. P. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors. Bioorg. Med. Chem. Lett., 2011, 21, 3738-3742.
62. Blank, J.; Kandt, M.; Pfeiffer, W.-D.; Hetzheim, A.; Langer, P. Domino cyclization of 2-isothiocyanatobenzonitrile with carboxylic hydrazides-One-pot synthesis of 1, 2, 4-triazolo[1, 5-c]quinazoline-5(6H)-thiones. Eur. J. Org. Chem., 2003, 1, 182-189.
63. Asproni, B.; Murineddu, G.; Pau, A.; Pinna, G. A.; Langgård, M.; Christoffersen, C. T.; Nielsen, J.; Kehler, J. Synthesis and SAR study of new phenylimidazole-pyrazolo[1, 5-c]quinazolines as potent phosphodiesterase 10A inhibitors. Bioorg. Med. Chem., 2011, 19, 642-649.
64. Alberti C. Gazz. Chim. Ital., 1957, 87, 772-780.
65. De Stevens, G., Halamandaris, A., Bernier, M., Blatter, H. M. J. Org. Chem., 1963, 28, 1336-1339.
66. Boehringer Ingelheim International GmbH. Lankau, H.-J.; Langen, B.; Grunwald, C.; Höfgen, N.; Stange, H.; Dost, R.; Egerland, U. (1, 2, 4)triazolo[4, 3-a]quinoxaline derivatives as inhibitors of phosphodiesterases. WO2012104293A1, August 9, 2012.